Benefits
Gut microbiome composition
In the one randomized trial of Odilia (80 adults with gut dysbiosis, 300 mg a day, 8 weeks), the Firmicutes to Bacteroidetes ratio fell from 2.72 to 1.56 within the Odilia group. But compared against placebo at 4 and 8 weeks, the groups were reported as still comparable, and the placebo ratio also fell (2.29 to 1.69). Bifidobacteria did not increase.
Digestive comfort and reflux symptoms
Over 8 weeks, digestive quality-of-life scores rose 19.6% on Odilia against 11.8% on placebo, and reflux symptom scores fell 53.8% against 40.0%; both gaps were statistically significant. Abdominal pain, fullness, belching and heartburn were among the items that improved. No stool diary or stool form scale was used, and 300 mg supplies very little fiber.
Fatigue and coping with stress (two questionnaire items)
Bionap markets Odilia for a gut-brain-muscle axis, but the trial measured no muscle outcome. Two single items in the digestive questionnaire, self-rated fatigue and coping with stress, improved more on Odilia than placebo at 8 weeks (+0.9 versus +0.3 and +0.9 versus +0.5 points). These are not validated fatigue or stress scales, and the study was not designed to test them.
Mechanism of action
Prebiotic fermentation
Opuntia poly- and oligosaccharides reach the colon where gut bacteria can ferment them. Laboratory work on Opuntia cladode mucilage found the large polysaccharides ferment poorly, only 11% to 27% as readily as glucose, with the smaller oligosaccharides doing better. Short-chain fatty acids have never been measured in any human study of this extract, so the SCFA step is inferred from other work, not observed.
Soluble-fiber mucilage
The cladode mucilage is a viscous soluble fiber. At 300 mg a day the amount delivered is tiny next to the gram doses used in bowel-regularity research, and no bowel-habit outcome has ever been measured with this extract. The trial authors themselves note that fiber supplements are usually dosed in grams.
Clinical trials
Randomized, double-blind, placebo-controlled, single-center parallel-group trial of Odilia 300 mg/day against a 300 mg maltodextrin placebo for 8 weeks, registered as ISRCTN14562892. Funded by Bionap, which sells Odilia; one author is a Bionap R&D employee, and the study was run at Nutratech (a Complife company). The sample size was calculated two-sided but the results were all tested one-sided. (Mellai et al. 2024, Nutrients)
80 healthy adults aged 25 to 50 with gut dysbiosis of unknown cause and BMI under 30 (76 completed, 38 per arm); smokers, pregnant women, people with unstable medical disease and anyone with a condition that could interfere with the treatment were excluded, so people with diagnosed bowel disease were not studied
Primary endpoint, stool 16S sequencing: within the Odilia group the Firmicutes to Bacteroidetes ratio fell from 2.72 to 1.56 (p = 0.0012) and Bacteroides and Clostridium XIVa increased. Those are before-and-after comparisons inside one arm. Compared against each other at 4 and 8 weeks the two groups were reported as still comparable, with no significant difference in diversity or bacterial signature, and the placebo group's ratio also fell, from 2.29 to 1.69. Secondary endpoints, the symptom questionnaires, were compared between groups: GIQLI +19.6% on Odilia versus +11.8% on placebo, and GSAS reflux symptoms -53.8% versus -40.0%, both significant at 8 weeks. Bifidobacteria decreased rather than increased. Body weight, BMI, waist and hip measurements did not change. Both products were well tolerated and nobody withdrew because of adverse events.